Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - brimonidine tartrate; brinzolamide -

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone palmitate 312 mg/ml equivalent to 175 mg/dose palperidone, as 273 mg/dose paliperidone palmitate;  ;   - suspension for injection - 175 mg - active: paliperidone palmitate 312 mg/ml equivalent to 175 mg/dose palperidone, as 273 mg/dose paliperidone palmitate     excipient: citric acid monohydrate macrogol 4000 monobasic sodium phosphate monohydrate polysorbate 20 sodium hydroxide water for injection - invega trinza, a 3-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone palmitate 312 mg/ml equivalent to 263 mg/dose palperidone, as 410 mg/dose paliperidone palmitate;  ;   - suspension for injection - 263 mg - active: paliperidone palmitate 312 mg/ml equivalent to 263 mg/dose palperidone, as 410 mg/dose paliperidone palmitate     excipient: citric acid monohydrate macrogol 4000 monobasic sodium phosphate monohydrate polysorbate 20 sodium hydroxide water for injection - invega trinza, a 3-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone palmitate 312 mg/ml equivalent to 350 mg/dose paliperidone, as 546 mg/dose paliperidone palmitate;  ;   - suspension for injection - 350 mg - active: paliperidone palmitate 312 mg/ml equivalent to 350 mg/dose paliperidone, as 546 mg/dose paliperidone palmitate     excipient: citric acid monohydrate macrogol 4000 monobasic sodium phosphate monohydrate polysorbate 20 sodium hydroxide water for injection - invega trinza, a 3-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone palmitate 312 mg/ml equivalent to 525 mg/dose paliperidone as 819 mg/dose paliperidone palmitate;  ;   - suspension for injection - 525 mg - active: paliperidone palmitate 312 mg/ml equivalent to 525 mg/dose paliperidone as 819 mg/dose paliperidone palmitate     excipient: citric acid monohydrate macrogol 4000 monobasic sodium phosphate monohydrate polysorbate 20 sodium hydroxide water for injection - invega trinza, a 3-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

janssen pharmaceuticals, inc - paliperidone palmitate (unii: r8p8usm8fr) (paliperidone - unii:838f01t721) - paliperidone palmitate 273 mg in 0.875 ml - invega trinza® (paliperidone palmitate), a 3-month injection, is indicated for the treatment of schizophrenia in patients after they have been adequately treated with invega sustenna® (1-month paliperidone palmitate extended-release injectable suspension) for at least four months [see dosage and administration (2.2) and clinical studies (14)] . invega trinza® is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the invega trinza® formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. paliperidone palmitate is converted to paliperidone, which is a metabolite of risperidone. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including invega trinza® , during pregnancy. healthcare providers are encouraged to